TransCode Therapeutics Updates SEC Filing to Report CVR Agreement Effective Date and Change in Rights Agent

Reuters
2025.10.17 21:09
portai
I'm PortAI, I can summarize articles.

TransCode Therapeutics Inc. has filed Amendment No. 2 to its Current Report on Form 8-K, reporting the effective date of its Contingent Value Rights (CVR) Agreement and a change in the rights agent. The CVR Agreement with Vstock Transfer, LLC is included as an exhibit in the filing.

TransCode Therapeutics Inc. has filed Amendment No. 2 to its Current Report on Form 8-K to report the effective date of its Contingent Value Rights (CVR) Agreement and to note a change in the rights agent. The executed CVR Agreement with Vstock Transfer, LLC is included as an exhibit in the filing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-100456), on October 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.